Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR‐TKIs) have shown significant efficacy in patients with brain metastases (BMs) from EGFR‐mutated non‐small cell lung cancer (NSCLC). The gene discussed is EGFR; the disease is non-small cell lung carcinoma.